Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors.
By Nagma Khan, M. Jeffers, Sampath Kumar, C. Hackett, F. Boldog, N. Khramtsov, Xiaozhong Qian, Evan Mills, S. Berghs, N. Carey and 7 more. Biochemical Journal, 2008
717 citations recorded by the source corpus.
Subfields: Molecular Biology, Oncology
View Paper: https://www.semanticscholar.org/paper/6a52875af70d1397078cf79878d215f6cd4080bc
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Molecular Biology
- W-S Xu
- Marcus Bantscheff
- Leslie M. Thompson
- Mikhail M. Savitski
- PA Marks
- A. Kazantsev
- Alexey I. Nesvizhskii
In Oncology
Citations in the corpus
- Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. (2011, background): “We also investigated the effect of TSA, a potent inhibitor of HDAC activity [30], on production of cytokines and NO by neutrophils.”
- Histone Deacetylase Inhibitors: Potential in Cancer Therapy (2009, background): “…isoform selective or specific inhibitors are currently in development [Haggarty et al., 2003; Somoza et al., 2004; Kozikowski et al., 2007; Rasheed et al., 2007; Butler and Kozikowski, 2008; Estiu et al., 2008; Khan et al., 2008; Moradei et al., 2008; Jones et al., 2008a; Schemies et al., 2009].”
- Therapeutic application of histone deacetylase inhibitors for central nervous system disorders (2008, background): “According to new findings, MS275 was found to be selective for HDAC1 (Ref”
- Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes (2011, background): “HDACs share a conserved substrate pocket, and most hydroxamate inhibitors are nonselectiv”
- Anti-inflammatory Agents: Present and Future (2010, neutral): “In humans, there are 18 HDACs divided into classes based on their dependence on zinc for enzymatic activity (Khan et al., 2008).”
- Multiple roles of HDAC inhibition in neurodegenerative conditions (2009, background): “Apicidin, a cyclic tetrapeptide, inhibits HDAC2 and 3 in the low nanomolar range and HDAC8 in the high nanomolar range, but does not affect HDAC1 or Class II HDACs [16].”